UPDATE: Keryx Announces Zerenex LT Phase 3 Results Shows 'Highly Statistically Significant' Change, Met Primary Endpoint
July 24, 2014 at 17:04 PM EDT
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) (the "Company") announced the publication of results from the long-term, randomized, ...